Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : The 56 Point TA; Charts With an Attitude -- Ignore unavailable to you. Want to Upgrade?

To: Doug R who wrote (60512)	10/8/2020 6:19:55 PM
From: Doug R	Respond to of 79273

GenMark Diagnostics’ ePlex® Respiratory Pathogen Panel 2 (RP2) Receives EUA from FDA finance.yahoo.com GlobeNewswire•. October 8, 2020 Combination test for COVID-19, flu and other common respiratory illnesses helps health care professionals prepare for flu season RP2 Panel at a Glance GenMark’s ePlex® Respiratory Pathogen Panel 2 (RP2 Panel) has received Emergency Use Authorization from the FDA. The RP2 Panel provides results in less than two hours for more than 20 viruses and bacteria that cause common respiratory infections with similar symptoms, including COVID-19, flu, bronchitis and the common cold. The rapid, multiplex molecular testing offered by the RP2 Panel will be vital in preparing for the fall and winter, when COVID-19 will be circulating along with flu and other common respiratory infections, helping doctors quickly and effectively treat seriously ill patients.